BioSpace News Archive

What do you expect to be different about your medical care this year? Expert physicians will respond to this question and other healthcare concerns webinar participants would like to discuss. It’s an opportunity for you to join in and ask medical questions.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in the H.C. Wainwright BioConnect Virtual Conference from January 10th to January 13th.

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next-generation bispecific immunotherapies to transform the lives of patients with cancer, today announced that it will participate in the H.C. Wainwright Bioconnect Conference and the B. Riley Securities’ 2022 Oncology Conference.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from 10-13 January 2022.

PaxMedica, Inc. today announced that it has received approval from the South African Health Products Regulatory Agency (SAHPRA) for its clinical trial application to study the effects of PAX-101.

Pharmaron Beijing Co., Limited today announced the appointment of Dr. Sid Bhoopathy as Senior Vice President, US Head of Laboratory Services and CGT, effective November 1, 2021.

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that John Caloz, the Company’s Chief Financial Officer, is scheduled to present at the H.C. Wainwright BioConnect Virtual Conference.

Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) today announced that it has entered into a loan agreement with investment funds managed by Pharmakon Advisors, LP.

Revance Therapeutics, Inc. today provided preliminary fourth quarter and full year 2021 financial results and a corporate update.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the virtual H.C. Wainwright BioConnect Conference.